Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Receivables (2023 - 2025)

Historic Receivables for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $1.2 billion.

  • Genmab A's Receivables rose 2216.55% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 2216.55%. This contributed to the annual value of $1.2 billion for FY2025, which is 2216.55% up from last year.
  • As of Q4 2025, Genmab A's Receivables stood at $1.2 billion, which was up 2216.55% from $979.0 million recorded in Q4 2024.
  • In the past 5 years, Genmab A's Receivables ranged from a high of $1.2 billion in Q4 2025 and a low of $786.0 million during Q4 2023
  • Its 3-year average for Receivables is $987.0 million, with a median of $979.0 million in 2024.
  • Its Receivables has fluctuated over the past 5 years, first soared by 2455.47% in 2024, then surged by 2216.55% in 2025.
  • Over the past 3 years, Genmab A's Receivables (Quarter) stood at $786.0 million in 2023, then grew by 24.55% to $979.0 million in 2024, then rose by 22.17% to $1.2 billion in 2025.
  • Its Receivables stands at $1.2 billion for Q4 2025, versus $979.0 million for Q4 2024 and $786.0 million for Q4 2023.